Chief Scientific Officer
research and drug development
United States of America
Dinah Sah is our Chief Scientific Officer. She has more than 20 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Sah has led multiple programs from early research through Phase 1 clinical trials, as well as discovering novel therapeutic targets and drug candidates that have advanced into clinical development. Before joining Voyager, Dr. Sah was at Alnylam Pharmaceuticals, where she was most recently vice president of research, providing scientific leadership and administrative oversight of discovery research and multiple research and development programs. At Alnylam, her leadership of several RNAi therapeutics R&D programs resulted in the landmark demonstration of human proof-of-mechanism for this novel class of drugs. Prior to Alnylam, Dr. Sah was associate director of research at Biogen, where she led neuroscience research and strategic planning for neurobiology, and before that, she headed neuroscience research at Signal Pharmaceuticals, where she also led multiple corporate partnerships and projects. Dr. Sah is an inventor on more than 25 patents, and her publications across diverse research areas include 18 articles in the New England Journal of Medicine, Nature Medicine, Nature Biotechnology, Nature Neuroscience, Nature Chemical Biology, Nature Reviews Drug Discovery, Molecular Therapeutics, Neuron, PNAS and EMBO Journal. Dr. Sah received a B.S. in biology from the Massachusetts Institute of Technology, a Ph.D. in neurobiology from Harvard University and completed her postdoctoral training at Harvard Medical School.
Medicine, Nature Medicine, Nature Biotechnology, Nature Neuroscience, Nature Chemical Biology, Nature Reviews Drug Discovery, Molecular Therapeutics, Neuron, PNAS and EMBO